References
- Cain B F, Seelye R N, Atwell G J. Potential antitumor agents. 14 Acridylmethanesulphonanilides. J Med Chem 1974; 17: 922–930
- Cain B F, Atwell G J. The experimental antitumor properties of three congeners of the acridylmethanesulphonanilide (AMSA) series. J Cancer 1974; 10: 539–549
- Furlong N B, Sato J, Brown T, Chavez F, Hurlbert R B. Induction of limited DNA damage by the antitumor agent Cain's acridine. Cancer Res 1978; 38: 1329–1335
- Gromley P E, Sethi V S, Cysyk R L. Interaction of 4'-(9-acridinylamino)methanesulfon-m-anisidide with DNA and inhibition of oncornavirus reverse transcriptase and cellular nucleic acid polymerases. Cancer Res 1978; 38: 1300–1306
- Legha S S, Gutterman J U, Hall S W, Benjamin R S, Burgess M A, Valdivieso M, Bodey G P. Phase I clinical investigation of 4'-(9-acridinylamino)methane-sulfon-m-aminsidide (NSC 249992), a new acridine derivative. Cancer Res 1978; 38: 3712–3716
- Von Hoff D D, Howser D, Gormely P, Bender R A, Glarbiger D., Levine A S, Young R C. Phase I study of methanesulfonamide, N-[4-(9-acridinylamino)-3-rnethoxy-phenyl]-(m-AMSA) using a single dose schedule. Cancer Treat Rep 1978; 62: 1421
- Legha S S, Keating M J, Zander A R, McCredie K B, Bodey G P, Freireich E J. 4-(9-Acridinylamino)methanesulfon-m-anisidide (AMSA): A new drug effective in the treatment of adult acute leukemia. Ann Intern Med 1980; 93(1)17–21
- Van Echo D A, Chiuten D F, Gormley P E, Lichtenfeld J L, Scoltock M, Wiernick P H. Phase I clinical and pharmacological study of 4'-(9-acridinylamino)-methanesulfon-m-anisidide using an intermittent biweekly schedule. Cancer Res 1979; 39: 3881–3884
- Wilson W R. Studies on the mechanism of action of an experimental antitumor drug. Chem NZ 1974; 37: 148–152
- Dawson H. The blood-brain barrier. J Physiol (London) 1976; 255: 1–28
- Fenstermacher J D, Johnson J A. Filtration and reflection coefficients of the rabbit blood-brain barrier. Am J Physiol 1966; 211–341